Effect of Pioglitazone Compared to a Combination Therapy With Ramipril and to a Ramipril Monotherapy on Low Grade Inflammation and Vascular Function in Patients With Increased Cardiovascular Risk and an Activated Inflammation. A Randomized Double-Blinded Phase II Study.

Trial Profile

Effect of Pioglitazone Compared to a Combination Therapy With Ramipril and to a Ramipril Monotherapy on Low Grade Inflammation and Vascular Function in Patients With Increased Cardiovascular Risk and an Activated Inflammation. A Randomized Double-Blinded Phase II Study.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2013

At a glance

  • Drugs Pioglitazone; Ramipril
  • Indications Hypertension; Insulin resistance
  • Focus Pharmacodynamics
  • Acronyms PIOace
  • Sponsors Takeda Pharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2006-004028-35).
    • 22 Oct 2009 Results presented at the 20th World Diabetes Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top